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i:10.1016/j.ejvs.2010.03.004In recent years, surgery has been used less and less in the
treatment of intermittent claudication. Reasons include
preoccupation with risk factor control and medical
management; evidence that supervised exercise increases
walking distance; and the inclination to use percutaneous
balloon angioplasty and/or stenting (PTA/S) in preference
to surgery whenever possible. Surgery is more invasive
than any of these other options with a risk of serious
complications. All this has led to a degree of peer pressure
against operations on claudicants, which can be particu-
larly difficult for younger specialists whose experience of
open arterial surgery is less than that of their predeces-
sors. We argue that avoidance of surgery for claudication is
not always justified, and that operations still offer
substantial benefit e but only in carefully selected
patients.
Good risk factor control is an essential pre-requisite to
intervention. A trial drug of therapy (e.g., cilostazol) is
reasonable for patients who are unsuitable for revascular-
isation, but is seldom enough for patients with high aspi-
rations. Supervised exercise programmes produce some
benefit, although many patients fail to complete them and
they have not been widely adopted. It could be argued that
exercise classes benefit a limited number of claudicants
who are satisfied with modest improvement.
None of the treatments above can restore walking ability
to normal in the presence of significant arterial occlusive
disease: only a revascularisation procedure can do that.
Sufficient time should have elapsed since the onset of
symptoms; and counselling should ensure that the patient is
sufficiently disabled to want intervention and its attendantty for Vascular Surgery. Publisherisks. Counselling can be challenging: some patients do not
seem to grasp the small but serious risks, or to balance
these wisely against their wish walk further.
Percutaneous transluminal angioplasty with or without
stenting (PTA/S) is always the intervention to consider first,
but the technical possibilities need to be weighed against
the likelihood of long term success. Decision making
contrasts with that in critical ischaemia, when long term
patency is of less importance.
Most of the evidence about surgery for claudication is
from before current standards of risk factor control and
specifically before statins: patencies may therefore be
better now. Publications have often mixed claudicants with
critical ischaemia patients, whose outcomes are poorer.1,2
Historical reports may therefore ‘‘undersell’’ the poten-
tial benefits of surgery for claudication.
For aortoiliac disease surgery can offer significantly
better patency rates for selected patients, but these need
to be balanced against occasional mortality and a greater
risk of complications, compared with PTA/S.1,3 Crossover
grafts (femorofemoral or iliofemoral) are often combined
with PTA/S for treating aortoiliac disease, with reasonable
results in the medium term for a low risk of complications
(around 6%) and mortality (around 1%). These, and unilat-
eral iliofemoral bypasses, seem reasonable to offer to
suitable claudicants who are sufficiently disabled. Local-
ised common femoral stenoses are more suitable for
endarterectomy than for PTA/S. Common femoral/pro-
funda endarterectomy is a relatively small procedure with
good expectation of long term patency and low operative
risk.4d by Elsevier Ltd. All rights reserved.
746 EditorialFemoropopliteal bypass grafts are the main area of
controversy. There is a lower threshold for offering PTA/S,
which is well justified for TASC A or B pattern disease, but
for TASC C and D disease vein bypass may be preferable for
long term patency in low risk patients.5 The substantially
lower patencies for synthetic femoropopliteal grafts argue
against offering synthetic grafts to claudicants.6
If femoropopliteal bypasses occlude only about 24%
patients areworse than before and only about 3e5% progress
to amputation7 (similar to the natural history of untreated
claudicants).8 Nevertheless, clinically obvious occlusion of
a surgical bypass does propel surgeons to early reinterven-
tion, in contrast to reocclusion after angioplasty. This may
not always be wise e especially after repeated occlusion of
synthetic bypasses, for which the outlook is poor.9
Decisions about interventions for claudicants are unlikely
to be better informed by controlled studies: recruitment
rates into randomised trials on claudication have been
disappointingly poor.10 Surgical procedures which can offer
a worthwhile chance of long term success, with relatively
low risk, are common femoral/profunda endarterectomy,
iliofemoral/femoral bypass and femoropopliteal bypass
using good autologous vein. Vascular specialists should not
feel remiss in offering these operations to carefully selected
claudicants who wish to walk further and whose quality of
life may be greatly enhanced as a result.
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